CMPS (COMPASS Pathways PLC) רווח נקי למניה אחת בשנים עשר החודשים האחרונים

The price trajectory for COMPASS Pathways plc (CMPS) shown below on the GURU.Markets platform reflects the EPS TTM dynamics, which currently stands at 15.80. This is supported by the pristine condition of laboratory facilities and a strict equipment maintenance protocol. The business focuses on developing psilocybin therapy for clinics, relying on insurance reimbursements, while outsourcing the development of new compounds to external contractors to keep formula ownership in-house.

COMPASS Pathways plc (CMPS) operational successes in ethical psychopharmacotherapy are reflected in the annual shift of EPS TTM. This indicator continuously compares the total earnings per share over the last 12 months with the same period last year. Such price action reveals hidden profitability trends by neutralizing quarterly volatility. It is critical for investors to assess this pace as a marker for the effective implementation of the company's ESG strategy and bioethical standards.